News

Kurin Inc. announces new Kurin PIV™ product to impact blood culture contamination

San Diego, CA: Kurin Inc., the inventor and manufacturer of 510(k) cleared Kurin® blood culture collection sets, announced the launch of its peripheral intravenous catheter (PIV) configuration to the patent-pending Kurin Lock™ product line. Kurin Lock technology passively diverts the initial aliquot of blood and any contaminants present therein to help hospitals in their efforts to reduce contaminated blood cultures. The Kurin PIV™ product connects directly to an IV catheter
as when a clinician collects a blood culture from a fresh IV start.

Roughly 20% of skin microbes reside deep in the dermis layer, unaffected by standard skin antisepsis, and may be drawn into blood samples. Typical collection sets provide microbes a direct line to the culture bottle. With no alternative, hospitals have accepted high rates of seemingly unavoidable false positive test results. As a result, approximately one-third of all
positive blood culture results are inaccurate, causing US hospitals to spend billions of dollars each year on non-existent bloodstream infections.

“We are pleased to add Kurin PIV to our offerings. Kurin now provides solutions for all blood culture collection practices, including times when a syringe is used to draw blood rather than employing the vacuum created by blood culture containers,” said Kurin CEO, Bob Rogers. “This is an exciting time. In addition to growing the Kurin product line, we are awaiting the publication of multiple clinical studies, all of which showed Kurin Lock use to significantly reduce false
positive blood cultures.”

Kurin PIV is the latest collection set configuration in a product suite including options for 21g and 23g butterfly safety needles and compatibility with BD Bactec®, bioMerieux BacT/Alert®, and Thermo Fisher VersaTREK™ EZ DRAW® and REDOX™ bottles. “In addition to requiring no change in clinical practice, Kurin requires only a fractional amount of blood, allowing for pediatric use. To our knowledge, Kurin is the only blood diversion product on the market to have FDA 510k clearance,” said Mr. Rogers.

About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Copyright © 2017 Kurin Inc. All rights reserved.